Resistance of human immunodeficiency virus type 1 to antiretroviral agents: A

Alejo Erice, Henry H. Balfour

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Resistance of human immunodeficiency virus (HIV) to available nucleoside reverse-transcriptase inhibitors, the only approved therapeutic agents for HIV infection, has been recognized since shortly after the initial trials of zidovudine. The rapid development of resistance of the virus to nonnucleoside reverse-transcriptase inhibitors has also been documented. Drs. Erice and Balfour ofthe University of Minnesota herein the current status of methods used to assay for such resistance, the possible use of combinations of antiretroviral agents to delay the development of resistance, and the potential clinical implications of a loss of susceptibility to these drugs. Resistance to zidovudine apparently is associated with immunologic deterioration; therefore, the provision of care to HIV-infected persons in the future may require an understanding of these issues.

Original languageEnglish (US)
Pages (from-to)149-156
Number of pages8
JournalClinical Infectious Diseases
Issue number2
StatePublished - Feb 1994


Dive into the research topics of 'Resistance of human immunodeficiency virus type 1 to antiretroviral agents: A'. Together they form a unique fingerprint.

Cite this